198 related articles for article (PubMed ID: 23320492)
1. Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.
Nishi R; Yamauchi T; Negoro E; Takemura H; Ueda T
Cancer Sci; 2013 Apr; 104(4):502-7. PubMed ID: 23320492
[TBL] [Abstract][Full Text] [Related]
2. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
[TBL] [Abstract][Full Text] [Related]
4. Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
Anticancer Res; 2014 Apr; 34(4):1657-62. PubMed ID: 24692694
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Nishi R; Shigemi H; Negoro E; Okura M; Hosono N; Yamauchi T
BMC Cancer; 2020 Oct; 20(1):984. PubMed ID: 33046037
[TBL] [Abstract][Full Text] [Related]
6. All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation.
Freund A; Rössig C; Lanvers C; Gescher A; Hohenlöchter B; Jürgens H; Boos J
Ann Oncol; 1999 Mar; 10(3):335-8. PubMed ID: 10355579
[TBL] [Abstract][Full Text] [Related]
7. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
Wang S; Vrana JA; Bartimole TM; Freemerman AJ; Jarvis WD; Kramer LB; Krystal G; Dent P; Grant S
Mol Pharmacol; 1997 Dec; 52(6):1000-9. PubMed ID: 9396780
[TBL] [Abstract][Full Text] [Related]
8. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W
Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
[TBL] [Abstract][Full Text] [Related]
11. Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.
Yamauchi T; Uzui K; Shigemi H; Negoro E; Yoshida A; Ueda T
Cancer Sci; 2013 Jul; 104(7):926-33. PubMed ID: 23557198
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cytarabine-resistant leukemic cell lines established from five different blood cell lineages using gene expression and proteomic analyses.
Negoro E; Yamauchi T; Urasaki Y; Nishi R; Hori H; Ueda T
Int J Oncol; 2011 Apr; 38(4):911-9. PubMed ID: 21290089
[TBL] [Abstract][Full Text] [Related]
13. Biochemical modulation of cytarabine triphosphate by clofarabine.
Cooper T; Ayres M; Nowak B; Gandhi V
Cancer Chemother Pharmacol; 2005 Apr; 55(4):361-368. PubMed ID: 15723262
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells.
Ibrado AM; Huang Y; Fang G; Liu L; Bhalla K
Cancer Res; 1996 Oct; 56(20):4743-8. PubMed ID: 8840993
[TBL] [Abstract][Full Text] [Related]
15. Intracellular metabolism of Ara-C and resulting DNA fragmentation and apoptosis of human AML HL-60 cells possessing disparate levels of Bcl-2 protein.
Bullock G; Ray S; Reed JC; Krajewski S; Ibrado AM; Huang Y; Bhalla K
Leukemia; 1996 Nov; 10(11):1731-40. PubMed ID: 8892676
[TBL] [Abstract][Full Text] [Related]
16. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
[TBL] [Abstract][Full Text] [Related]
17. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
18. Resistance to mitochondrial- and Fas-mediated apoptosis in human leukemic cells with acquired resistance to 9-beta-D-arabinofuranosylguanosine.
Månsson E; Stridh H; Albertioni F
Biochem Biophys Res Commun; 2002 Nov; 298(3):338-44. PubMed ID: 12413945
[TBL] [Abstract][Full Text] [Related]
19. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
Fu CH; Martin-Aragon S; Weinberg KI; Ardi VC; Danenberg PV; Avramis VI
Cancer Chemother Pharmacol; 2001 Aug; 48(2):123-33. PubMed ID: 11561778
[TBL] [Abstract][Full Text] [Related]
20. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
